ReviewJournal of thrombosis and thrombolysis2011
Antiplatelet agents in cardiovascular disease.
Review in Journal of thrombosis and thrombolysis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Synthesis and Antiplatelet Activity Evaluation of a Group of Novel Ethyl Acetoacetate Phenylhydrazone Derivatives.Iranian journal of pharmaceutical research : IJPR · 2021Article
- [Traumatic brain injury in anticoagulated patients : Hemostatic therapy for the treatment of intracranial hemorrhage].Der Unfallchirurg · 2017Article
- A novel indication of platonin, a therapeutic immunomodulating medicine, on neuroprotection against ischemic stroke in mice.Scientific reports · 2017Article
- Platelet secretion and hemostasis require syntaxin-binding protein STXBP5.The Journal of clinical investigation · 2014Article
- Antiplatelet and anticoagulant effects of diterpenes isolated from the marine alga, Dictyota menstrualis.Marine drugs · 2014Article
- Clinical review: Traumatic brain injury in patients receiving antiplatelet medication.Critical care (London, England) · 2012Review
- Evaluation of Marine Brown Algae and Sponges from Brazil as Anticoagulant and Antiplatelet Products.Marine drugs · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite improvements in the treatment of acute coronary syndromes (ACS), cardiovascular disease remains the leading cause of death in the United States. Antiplatelet agents, such as aspirin and clopidogrel, play an important role in the treatment of patients with ACS, particularly those at high risk for whom treatment may yield the greatest benefits. The main challenge in preventing and managing ACS is to tailor treatment for each patient by taking into consideration patient characteristics, comorbidities, underlying short- and long-term risk factors, ischemic and bleeding risks, and expected individual responses to different medications. Several new alternatives providing more rapid and consistent platelet inhibition than aspirin and clopidogrel have been introduced for routine treatment of patients with ACS. These new treatments seem to provide additional benefits without a significant increase in the risk of bleeding, if used for the appropriate patients. In this article, we review the new antiplatelet agents being developed as well as their pharmacological characteristics, potential clinical indications, and key interactions with other antithrombotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.